|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_on1162403086 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
120206s2012 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020679068
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d VLY
|d OCLCO
|d N$T
|d E7B
|d OCLCF
|d YDXCP
|d EBLCP
|d AGLDB
|d VTS
|d AU@
|d STF
|d K6U
|d OCL
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 833089060
|
| 020 |
|
|
|a 9781620811887
|q (epub)
|
| 020 |
|
|
|a 162081188X
|
| 020 |
|
|
|z 9781620811450
|q (hardcover)
|
| 020 |
|
|
|z 1620811456
|
| 029 |
1 |
|
|a DEBBG
|b BV042794394
|
| 029 |
1 |
|
|a DEBSZ
|b 472777513
|
| 035 |
|
|
|a (OCoLC)1162403086
|z (OCoLC)833089060
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a QP572.A5
|
| 072 |
|
7 |
|a MED
|x 075000
|2 bisacsh
|
| 072 |
|
7 |
|a SCI
|x 036000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 612/.405
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Androgens :
|b production, functions, and disorders /
|c Berkley F. Thompson and Devon J. Robinson, editors.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical/Nova Science Publishers, Inc.,
|c [2012]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Endocrinology research and clinical developments
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record and CIP data provided by publisher.
|
| 546 |
|
|
|a English.
|
| 505 |
0 |
|
|a ANDROGENS ; ANDROGENS ; Contents ; Preface ; Androgen Deprivation Therapy for Advanced Prostate Cancer on the Ground of Androgen Milieu in the Prostate; Abstract ; Abbreviations ; Introduction; Androgen Milieu in Blood ; Androgen Milieu in the Prostate; Prostate Cancer Aggressiveness and the Androgen Milieu in the Prostate and in Blood ; Intraprostatic Androgen Milieu during Androgen Deprivation Therapy ; Androgen Milieu in the Castration-Resistant Prostate Cancer ; Clinical-Translational Advances of Prostate Cancer ; Gonadotrophin-Releasing Hormone (GnRH) Antagonists: Degarelix.
|
| 505 |
8 |
|
|a Cytochrome P450, Family 17, Subfamily A, Polypeptide 1 (CYP17A1) InhibitorsAbiraterone Acetate (Zytiga, Johnson & Johnson) ; Orteronel (TAK-700) [(1S)-1-(6,7-Dimethoxy-2-Naphthyl)-1-(1H-Imidazol-4-Yl)-2-Methylpropan-1-Ol] ; TOK-001 (VN/124-1) [3 -Hydroxy-17-(1H-Benzimidazole-1-Yl)Androsta-5,16-Diene] ; 3.-Hydroxysteroid Dehydrogenase Inhibitors; Apoptone (HE3235) (17 -Ethynyl-5 -Androstan-3, 17 -Diol) ; Inhibitors Targeting Androgen Receptor; A New Androgen Receptor Antagonist, MDV3100 ; A New Androgen Receptor Antagonist, ARN-509.
|
| 505 |
8 |
|
|a An Inhibitor of the Amino Terminal Domain (NTD) of the AR: EPI-001 The Prospects of the Androgen Deprivation Therapy on the Ground of Androgen Milieu in the Prostate ; Conclusion ; References ; Clinical Model of Androgen Deficiency -- Clinical Model of Androgen Deficiency -- Clinical Model of Androgen Deficiency -- Androgen Deprivation Therapy and Its Effect on Bone Metabolism, Metabolism and Cognitive Functions ; Introduction; Methods ; Androgen Deprivation Therapy (ADT) ; Testosterone: A Basal Overview of Biosynthesis, Metabolism and Its Action ; Androgens and Bone Metabolism.
|
| 505 |
8 |
|
|a ADT and Its Side Effects Bone Loss and Osteoporosis ; Osteoporosis; Diagnosis of Osteoporosis ; ADT, PCa and Clinical Aspects of Bone Disease ; Treatment of ADT Induced Osteoporosis ; Androgens and Cognitive Functions ; Potential Mechanisms of Action ; Cognitive Functions and ADT; Androgen Deprivation Therapy and Changes in Body Composition ; ADT and Insulin Resistance ; Early Metabolic Changes ; Late Metabolic Changes ; ADT and Lipid Alterations ; ADT, Metabolic Syndrome and Cardiovascular Disease ; References; The Role of Testosterone in Male Erectile Dysfunction.
|
| 505 |
8 |
|
|a 1. Erectile Dysfunction 2. Definitions; 2.1. Total Testosterone ; 2.2. Free Testosterone ; 2.3. Bio-Available/Bioactive Testosterone ; 3. Hypogonadism ; 3.1. Late Onset Hypogonadism ; 3.2. Hypogonadism Prevalence ; 4. Relationship between Testosterone and ED ; 5. Physiology of Erection ; 6. Influence of Testosterone on Penile Erection ; 6.1. NOS/cGMP Pathway ; 6.2. Source of NO ; 6.3. Phosphodiesterases (PDE); 7. Making the Diagnosis of Hypogonadism and Working up Erectile Dysfunction ; Patient History ; Physical Exam ; Laboratory Studies ; Specific Diagnostic Tests ; 7.1. Questionnaires.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Androgens.
|
| 650 |
|
0 |
|a Androgens
|x Pathophysiology.
|
| 650 |
|
2 |
|a Androgens
|
| 650 |
|
6 |
|a Androgènes.
|
| 650 |
|
6 |
|a Androgènes
|x Physiopathologie.
|
| 650 |
|
7 |
|a MEDICAL
|x Physiology.
|2 bisacsh
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Human Anatomy & Physiology.
|2 bisacsh
|
| 650 |
|
7 |
|a Androgens
|x Pathophysiology
|2 fast
|
| 650 |
|
7 |
|a Androgens
|2 fast
|
| 700 |
1 |
|
|a Thompson, Berkley F.,
|e editor.
|
| 700 |
1 |
|
|a Robinson, Devon J.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Androgens
|d New York : Nova Biomedical/Nova Science Publishers, Inc., [2012]
|z 9781620811450 (hardcover)
|w (DLC) 2012932562
|
| 830 |
|
0 |
|a Endocrinology research and clinical developments.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541149
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3021186
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10681386
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 541149
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 7586406
|
| 994 |
|
|
|a 92
|b IZTAP
|
